Circio Holding ASA · OSL:CRNA
Circio Holding ASA — Targovax — Investor Day (2021)
8 slides from Circio Holding ASA's investor day presentation, Apr 14, 2021
Slide 1: Preclinical pipeline update
Preclinical pipeline update 6. 4Q update 7. Closing remarks
Slide 2: Product candidate pipeline: preclinical, Phase 1, Phase 2
Product candidate Preclinical Phase 1 Phase 2 Collaborator Melanoma Combination w/Keytruda Colorectal cancer Combination w/Imfinzi Mesothelioma ONCOS-102 Combination w/pemetrexed/cisplatin ONCOS-200 series Next Gen viruses Novel mutRAS concepts 66
Slide 3: Targovax's three-pillar R&D pipeline strategy
TARGOVAX´S THREE-PILLAR R&D PIPELINE STRATEGY Novel ONCOS-102 combinations o Maximize clinical impact of ONCOS-102 through novel clinical combinations with complementary mechanism of action o Strong scientific rationale from existing clinical immune data Next Generation ONCOS viruses o Build new fun
Slide 4: Next generation ONCOS: ONCOS-211 prioritized for further development
NEXT GENERATION ONCOS: ONCOS-211 PRIORITIZED FOR FURTHER DEVELOPMENT Adenosine – a key suppressor of immune cells Transgene activity Transgene 1 – ICOS-L o ICOS-ligand binds to ICOS on the T- cell surface, providing a strong stimulatory signal o Enhanced cytotoxicity Transgene 2 – ADA o ADA degrades
Slide 5: ICOS-L expression can be tied to deep clinical response to ONCOS-102
ICOS-L EXPRESSION CAN BE TIED TO DEEP CLINICAL RESPONSE TO ONCOS-102 Immune cell infiltrate at Baseline, mIHC Co-stimulatory receptor expression, gene expression High Medium Low PD SD PR CR PD SD PR CR CR patient was …but high level of ICOS-L immunologically providing co-stimulatory signal “cold” at
Slide 6: Building tyrosine kinase inhibitor functionality into ONCOS
BUILDING TYROSINE KINASE INHIBITOR FUNCTIONALITY INTO ONCOS Collaboration partner Target – Tyrosine kinase inhibition Papyrus Therapeutics OPCML protein o OPCML is a potent tumor suppressor, inactivated in ca. 50% of all cancers o OPCML shuts down the oncogenic signaling function of at least 8 RTKs
Slide 7: Novel mutant RAS vaccination concepts incorporating immunological power of ONCOS
NOVEL MUTANT RAS VACCINATION CONCEPTS INCORPORATING IMMUNOLOGICAL POWER OF ONCOS Merging ONCOS and TG technology ONCOS used as carrier for mutRAS peptides Combining the power of mutRAS vaccination ONCOS-102 Modified TG ONCOS-TG and oncolysis peptides PeptiCRAd 71
Slide 8: R&D pipeline strategy designed to address key components of the cancer immunity cycle
THE R&D PIPELINE STRATEGY IS DESIGNED TO ADDRESS KEY COMPONENTS OF THE CANCER IMMUNITY CYCLE T-cell migration and 2 infiltration into the tumor Antigen release, cross- 1 presentation and priming of T-cells • Secretion of chemokines • Antigen release by ICD • TLR activation Expansion and survival of